Bigfoot Biomedical Inc. has closed a $55 million series B round – providing enough runway, the company said, to bring two diabetes products to market. In 2020, Bigfoot will submit FDA applications for both its infusion pump-based closed loop automated insulin delivery system, known as Bigfoot Loop, and its connected insulin pen-based system, known as Bigfoot Inject. To get there, development must be completed in the next year. It will then seek IDE approvals for pivotal trials to be conducted in 2019. The strategy now is to line up the products, data and approvals that will get all the way to FDA commercialization in 2020.